Billy [Analyst]'s questions to OPKO Health Inc (OPK) leadership • Q1 2025
Question
Billy, on behalf of Eric Joseph at JPMorgan, asked if the Phase 1 EBV vaccine trial would yield any efficacy or biomarker signals and requested an update on the timeline for the MDX2001 safety readout and dosing cohorts.
Answer
Executive Elias Zerhouni explained that while the EBV trial's primary endpoint is safety, it will provide immunogenicity data via biomarkers, offering indirect efficacy insights. For MDX2001, he noted the trial has advanced to the fourth of six initial dose levels and expects to complete this phase by year-end, establishing an efficacy range before moving to Phase 1b.